Moderna Tumbles 23.5% After 177% Surge on Cancer Vaccine Win, August 21

Moderna’s stock plunged 23.5% to HK$1,036 on August 21, erasing a third of its historic 177% gain from the prior day. The biotech firm’s personalized cancer vaccine, developed with Merck, succeeded in a Phase 3 trial for melanoma, but the speed of the rally triggered profit-taking. Meyka grades MRNA a B with a 12-month forecast of $58.61, suggesting the stock remains far above fair value after the spike.

The vaccine breakthrough and the wild ride

Moderna and Merck announced Wednesday that their mRNA-based cancer vaccine, called intismeran, met its primary goal in a Phase 3 trial involving over 1,100 melanoma patients. The vaccine combined with Merck’s Keytruda reduced the risk of cancer recurrence and spread compared to Keytruda alone. Moderna CEO Stephane Bancel called it “a big moment for medicine.” On August 19, Moderna surged 177% to $176.66, its highest level in over three years. By Thursday morning, the stock had fallen 23.5% to $133.32 as traders locked in gains.

Technical extremes signal caution

Moderna’s relative strength index (RSI) hit 92.21 on Wednesday, the highest reading in the stock’s history. An RSI above 70 is typically considered overbought. The rally pushed the stock decisively above its 50-day, 100-day, and 200-day moving averages, confirming a broad technical breakout. However, such extreme momentum often precedes sharp pullbacks. Short sellers suffered roughly $5.5 billion in paper losses on Wednesday, according to S3 Partners, but the pullback Thursday provided relief for bearish positions.

Analyst views diverge on the path forward

Jefferies analyst Tycho Peterson called the update “an important proof point for mRNA modality beyond legacy COVID,” noting potential winners in bioprocessing and life science tools. Bank of America analyst Alec Stranahan said the results represent “a watershed moment for Moderna,” allowing the company to diversify away from infectious disease. William Blair analyst Myles Minter upgraded his rating to outperform, citing a clear line of sight to revenue diversification. Yet Meyka’s C-minus rating reflects weak fundamentals: the company posts negative earnings per share of $8.15 and negative free cash flow.

What comes next for approval and revenue

Merck and Moderna plan to discuss the vaccine with regulators “in the next few months,” according to Dr. Dean Li, president of Merck Research Laboratories. The companies will present full data at an oncology conference before filing for approval. The timeline to U.S. approval remains uncertain, but the Phase 3 trial is the last stage before seeking regulatory approval. Moderna expects thousands of melanoma patients could benefit within the first few years of approval, opening a market worth over $240 billion according to some estimates.

Final Thoughts

Moderna’s 23.5% pullback reflects profit-taking after an extreme 177% rally, not a change in the vaccine’s science. With Meyka grading the stock B and forecasting $58.61 by year-end, the risk-reward remains tilted toward caution despite the breakthrough.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.